ClinicalTrials.gg
RecruitingNCT06484868Updated Jul 3, 2025

Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

A Phase 4 interventional study of Metreleptin in Partial Lipodystrophy, sponsored by Amryt Pharma. Recruiting at 12 sites in 4 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-07-03.

Sponsored by Amryt Pharma (part of Chiesi Farmaceutici S.p.A.) · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Feb 2024, registered Jun 2024).
  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Study summary

This is an Open Label, Phase IV, Post Authorisation Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in people with Partial Lipodystrophy

02

Conditions studied

  • Partial Lipodystrophy

Keywords

  • Metreleptin
03

In context

Lead sponsor

Amryt Pharma is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

First submitted after Amryt Pharma became part of Chiesi Farmaceutici S.p.A..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of familial or acquired partial lipodystrophy

Exclusion criteria

Exclusion Criteria:

  • Treatment with any Medicinal Product (IMP) within 6 months or 5 times the terminal half-life of the corresponding IMP, whichever is longer, before the screening visit.

Other protocol defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Metreleptin

    Metreleptin \[Recombinant-methionyl human Leptin; r-metHuLeptin\] for daily injection is a sterile, white, solid lyophilised cake

    Drug: Metreleptin

Interventions

  • Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency

06

What researchers measure

Primary outcomes

  1. Number of patients with decrease of at least 0.5% in glycated haemoglobin (HbA1c) at Month 12 compared to Baseline or HbA1c <6.5 % at Month 12, in patients with baseline HbA1c ≥6.5%.

    To evaluate the efficacy (HbA1c) of metreleptin treatment in patients with PL

    Time frame: 12 months

  2. Number of patients with decrease of at least 30% in triglycerides (TG) at Month 12 compared to Baseline, in patients with baseline TG levels ≥500 mg/dL (5.65 mmol/L)

    To evaluate the efficacy (TG) of metreleptin treatment in patients with PL

    Time frame: 12 months

Secondary outcomes

  1. Number of patients with decrease of at least 0.5% in HbA1c at Month 24 compared to Baseline or HbA1c <6.5 % at Month 24, in patients with baseline HbA1c ≥6.5%.

    To evaluate the long-term efficacy of metreleptin treatment in patients with PL

    Time frame: 24 months

  2. Number of patients with decrease of at least 30% in TG levels at Month 24 compared to Baseline, in patients with baseline TG levels ≥500 mg/dL (5.65 mmol/L).

    To evaluate the long-term efficacy of metreleptin treatment in patients with PL

    Time frame: 24 months

  3. Change from baseline in liver volume at Month 12 and Month 24

    To assess changes in liver volume.

    Time frame: 12 months and 24 months

  4. Incidence of, Treatment emergent adverse events (TEAEs), Deaths and other serious adverse events (SAEs), Treatment related adverse events (AEs), AEs of special interest (AESIs) and AEs leading to study drug discontinuation

    To evaluate the safety of metreleptin treatment in patients with PL

    Time frame: 24 months

07

Study locations

9 of 12 sites recruiting
  • Centre Hospitalier Régional Universitaire de Lille (CHRU) - Hôpital Claude Huriez
    Lille, France
    Recruiting
    • Marie-Christine Vantyghem · Contact
  • Hopital Pitie-Salpetriere
    Paris, France
    Recruiting
    • Fabrizio Andreelli · Contact
  • Hôpital Saint-Antoine
    Paris, France
    Recruiting
    • Corinne Vigouroux · Contact
  • Centre Hospitalier Lyon-Sud
    Pierre-Bénite, France
    Recruiting
    • Emmanuel Disse · Contact
  • Charite-Universitaetsmedizin Berlin - Campus Charite Mitte (CCM)
    Berlin, Germany
    Recruiting
    • Thomas Bobbert · Contact
  • Universitaetsklinikum Ulm - Klinik fuer Kinder- und Jugendmedizin
    Ulm, Germany
    Not yet recruiting
    • Martin Wabitsch · Contact
  • Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi
    Bologna, Italy
    Recruiting
    • Alessandra Gambineri · Contact
  • Universitá degli Studi "Magna Graecia" di Catanzaro
    Catanzaro, Italy
    Not yet recruiting
    • Antonio Aversa · Contact
  • Azienda Ospedaliero Universitaria Maggiore della Carità di Novara
    Novara, Italy
    Recruiting
    • Flavia Prodam · Contact
  • Azienda Ospedaliero Universitaria Pisana - Stabilimento di Cisanello
    Pisa, Italy
    Recruiting
    • Giovanni Ceccarini · Contact
  • A.S.U Integrata di Udine - Presidio Ospedaliero Santa Maria della Misericordia
    Udine, Italy
    Recruiting
    • Annalisa Sechi · Contact
  • Cambridge University Hospitals NHS Foundation Trust - Addenbrookes Hospital
    Cambridge, United Kingdom
    Not yet recruiting
    • Anna Stears · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2024 (actual). Primary completion is estimated for Feb 2028, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2024
First posted
Jul 3, 2024
StartActual
Feb 8, 2024
Primary completionEst.
Feb 2028
CompletionEst.
Feb 2028
Last update
Jul 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06484868
Lead sponsor
Amryt Pharma
Responsible party
Sponsor
First posted
Jul 3, 2024
Start date
Feb 8, 2024
Primary completion
Feb 2028 (estimated)
Completion
Feb 2028 (estimated)
Last update
Jul 3, 2025

Study contacts

Janet Boylan
Contact
clinicaltrials_info@chiesi.com
+3905212791

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metreleptin

Start the discussion